子宫内膜癌分子分型与PD-1/PD-L1阻断治疗

摘要

Endometrial cancer is one of the three common cancer of the female genital tract. According to the molecular char-acteristics of endometrial cancer.The cancer genome atlas proposed four molecular subtypes:POLE (DNA polymerase ε,POLE) mutant;microsatellite instability hypermutation;low copy number and high copy number/serous. Numerous preclinical and clinical researches indicated that PD-1/PD-L1 blockade therapy is a promising method for immunotherapy of endometrial cancer. The subtypes of POLE mutant and MSI hypermutation in endometrial cancers are characterized by high tumor mutation burden which may benefit from the treatment of PD-1/PD-L1 blockade. This molecular classification of endometrial cancer provides a new clinical treatment strategy for individualized immunotherapy.%子宫内膜癌是女性生殖道三大恶性肿瘤之一.癌症基因图谱计划根据子宫内膜癌的分子特征提出了POLE (DNA polymerase ε,POLE)突变型;微卫星不稳定高突变型;拷贝数低型和拷贝数高型/浆液性四种分子亚型.大量临床前和临床研究表明,PD-1/PD-L1阻断治疗是极具潜力的子宫内膜癌免疫治疗方法,子宫内膜癌中的POLE突变型和MSI高突变型具有肿瘤突变负荷较高的特征,可能是PD-1/PD-L1阻断治疗的获益人群.该分子分型为子宫内膜癌个体化免疫治疗提供了新的临床治疗策略.